|
| Study, year | Country | Setting | Intervention | Patients randomized | Mean age, yrs | Baseline renal function ∞ | Reported outcomes | Jadad
score |
| NP | Control | NP | Control | NP | Control |
|
|
Akamatsu et al., 2005 [4] | Japan | Live donor liver transplantation (recipients with model for end-stage liver disease scores >15) | Synthetic hANP infusion 0.05 to 0.1 μg/kg/min for 5 days | 19 | 18 | 48 | 51 | 48 ± 22 | 51 ± 18 | AKI requiring RRT, mortality, adverse events | 3 |
|
| Brenner et al., 1995 [22] | Germany | Heart transplantation | Urodilatin 40 ng/kg/min for 6 days | 12 | 12 | NR | 147 ± 30 | 102 ± 19 | AKI requiring RRT, duration of RRT, mortality, adverse events | 5 |
|
| Gianello et al., 1995 [23] | Denmark | Cadaveric renal transplantation | Synthetic hANP 100 μg bolus into renal allograft artery followed by infusion at 0.01 to 0.03 μg/kg/min until serum creatinine <2 mg/dL | 20 | 20 | 36 | 38 | NR | AKI requiring RRT, mortality, adverse events | 4 |
|
| Kuse et al., 1996 [24] | Germany | Liver transplantation (recipients with emerging ARF with criteria such as refractory anuria/oliguria <0.5 mL/kg/hr, increase in serum creatinine ≥200% or BUN ≥25 mmol/L) | Urodilatin at 20 ng/kg/min for 7 hours | 5 | 4 | 49 | 44 | 2.0 ± 1.4 | 2.3 ± 1.1 | AKI requiring RRT, mortality, adverse events | 4 |
|
| Langrehr et al., 1997 [25] | Denmark | Liver transplantation | Urodilatin at 20 ng/kg/min for 7 days | 33 | 37 | 44 | 47 | 1.2 ± 0.1 | 1.0 ± 0.1 | AKI requiring RRT, mortality, adverse events | 2 |
|
| Ratcliffe et al., 1991 [26] | United States | Cadaveric renal transplantation | Atriopeptin 0.0125 to 0.1 μg/kg/min for 12 hours | 19 | 19 | NR | NR | 1.1 ± 0.4 | 1.0 ± 0.4 | AKI requiring RRT, mortality, posttransplant CrCl, adverse events | 5 |
|
| Sands et al., 1990 [6] | United States | Cadaveric renal transplantation | Synthetic hANP 50 μg bolus followed by 0.1 μg/kg/min for 4 hours | 10 | 10 | 44 | 41 | NR | AKI requiring RRT, mortality, posttransplant CrCl, adverse events | 3 |
|
